Sarepta Therapeutics, Inc. Sample Contracts

Sarepta Therapeutics, Inc. – c/o Sarepta Therapeutics, Inc. (February 28th, 2019)
Sarepta Therapeutics, Inc. – Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments (February 27th, 2019)

-Presented positive preliminary clinical data from the Limb-girdle muscular dystrophy (LGMD) Type 2E program, MYO-101, 51% beta-sarcoglycan gene expression, exceeding the threshold of ≥20% of beta-SG positive fiber expression above baseline in patients dosed at 5E13vg/kg-

Sarepta Therapeutics, Inc. – 3,817,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 par value) EQUITY UNDERWRITING AGREEMENT (November 9th, 2018)
Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (October 31st, 2018)

The above-named Participant (the “Participant”) has been granted the number of restricted stock units (the “RSUs”) set forth below giving the Participant the conditional right to receive, without payment therefor, one share of Common Stock of Sarepta Therapeutics, Inc. (the “Company”) with respect to each RSU forming part of the award, pursuant and subject to the terms and conditions of the 2018 Equity Incentive Plan (the “Plan”) and this Restricted Stock Unit Award Agreement, including this Notice of Restricted Stock Unit Grant (the “Notice of Grant”) and the Terms and Conditions of Restricted Stock Unit Grant attached hereto as Exhibit A, (this “Award Agreement”), as follows:

Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN STOCK APPRECIATION RIGHT AWARD AGREEMENT (STOCK SETTLED) (October 31st, 2018)

The above-named Participant (the “Participant”) has been granted a stock appreciation right (the “SAR”) relating to the number of shares of Common Stock of Sarepta Therapeutics, Inc., (the “Company”) set forth below (the “Shares”), to be settled in Common Stock upon exercise, pursuant to the terms and conditions of the 2018 Equity Incentive Plan (the “Plan) and this Stock Appreciation Right Award Agreement (Stock Settled), including this Notice of Stock Appreciation Right Grant (the “Notice of Grant”) and the Terms and Conditions of Stock Appreciation Right Award attached hereto as Exhibit A (together, this “Award Agreement”) as follows:

Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT (October 31st, 2018)

The above-named Participant (the “Participant”) has been granted an Option (the “Option”) to purchase the number of shares of Common Stock of Sarepta Therapeutics, Inc. (the “Company”) set forth below (the “Shares”), pursuant and subject to the terms and conditions of the 2018 Equity Incentive Plan (the “Plan”) and this Stock Option Award Agreement, including this Notice of Stock Option Grant (the “Notice of Grant”) and the Terms and Conditions of Stock Option Grant attached hereto as Exhibit A, (together, this “Award Agreement”), as follows:

Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN (October 31st, 2018)

The above-named Participant (the “Participant”) has been granted the number of shares (the “Shares”) of restricted Common Stock of Sarepta Therapeutics, Inc. (the “Company”) set forth below (the “Restricted Stock”), pursuant and subject to the terms and conditions of the 2018 Equity Incentive Plan (the “Plan”) and this Restricted Stock Award Agreement, including this Notice of Restricted Stock Grant (the “Notice of Grant”) and the Terms and Conditions of Restricted Stock Grant attached hereto as Exhibit A, (this “Award Agreement”), as follows:

Sarepta Therapeutics, Inc. – Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments (October 24th, 2018)

CAMBRIDGE, Mass., October 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2018.

Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN (August 8th, 2018)
Sarepta Therapeutics, Inc. – Sarepta Therapeutics, Inc. EMPLOYMENT AGREEMENT (August 8th, 2018)

EMPLOYMENT AGREEMENT (this “Agreement”) between Sarepta Therapeutics, Inc., a Delaware corporation (the “Company”), and Dr. Gilmore N. O’Neill (the “Executive”), effective as of June 7, 2018 (the “Effective Date”), subject to and conditioned upon the Executive’s commencement of employment with the Company on such date.

Sarepta Therapeutics, Inc. – Re: Amendments to Employment Agreement and CIC Severance Agreement (August 8th, 2018)

This letter agreement (“Letter Agreement”) amends, effective on the date above, certain terms of the Change in Control and Severance Agreement (the “CIC Severance Agreement”) dated June 26, 2017 between you and Sarepta Therapeutics, Inc. (the “Company”) and the Employment Agreement (the “Employment Agreement”) dated June 26, 2017 between you and the Company.  Capitalized terms not otherwise defined in this Letter Agreement have the meanings set forth in the CIC Severance Agreement.  Except as provided herein, the CIC Severance Agreement and Employment Agreement will continue in accordance with their terms.

Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (August 8th, 2018)

Unless otherwise defined herein, the terms defined in the 2014 Employment Commencement Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement (the “Award Agreement”).

Sarepta Therapeutics, Inc. – CHANGE IN CONTROL AND SEVERANCE AGREEMENT (August 8th, 2018)

This Change in Control and Severance Agreement (the "Agreement") is made and entered into by and between Gilmore O’Neill, M.D. (the "Executive") and Sarepta Therapeutics, Inc. (the "Company"), effective as of June 7, 2018 (the “Effective Date”), subject to and conditioned upon the Executive’s commencement of employment with the Company on such date.

Sarepta Therapeutics, Inc. – AMENDMENT NO. 2 TO THE SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN (August 8th, 2018)

WHEREAS, Sarepta Therapeutics, Inc. (the “Company”) previously adopted and approved the 2014 Employment Commencement Incentive Plan (the “Plan”) as an inducement stock plan under Nasdaq Stock Market Rule 5635(c)(4) to, among other things, attract and retain the best candidates for positions of substantial responsibility upon whose judgment, interest, and special effort the successful conduct of the Company’s operation will be largely dependent; and

Sarepta Therapeutics, Inc. – GENERAL RELEASE AND AMENDMENT TO SEPARATION AGREEMENT (May 3rd, 2018)

GENERAL RELEASE AND AMENDMENT TO SEPARATION AGREEMENT (the “Release/Amendment”), by Dr. Catherine Stehman-Breen, M.D., M.S. (the “Executive”) in favor of Sarepta Therapeutics, Inc. (the “Company”) and the Company Releasees (as hereinafter defined), dated as of December 15, 2017.

Sarepta Therapeutics, Inc. – SPONSORED RESEARCH AGREEMENT (May 3rd, 2018)

THIS SPONSORED RESEARCH AGREEMENT (this "Agreement"), effective the 12th day of October, 2007 (the "Effective Date"), is entered into by and between AVI  BIOPHARMA, INC., an Oregon Corporation, with principal offices located at One SW Columbia, Suite 1105, Portland, Oregon 97258 ("Company"), and CHARLEY'S FUND, INC., a 501(c)(3) tax-exempt public non-profit organization with a mailing address of P.O. Box 297, South Egremont, MA, 01258 (the "Sponsor").

Sarepta Therapeutics, Inc. – FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENT (May 3rd, 2018)

This FIRST AMENDMENT TO SPONSORED RESEARCH AGREEMENT (the “Amendment”) is entered into effective as of May 28, 2009 (“Amendment Date”), by and between AVI BioPharma, Inc., an Oregon corporation having offices at 4575 SW Research Way, Suite 200, Corvallis, OR 97333 (the “Company”), and Charley's Fund, Inc., a 501(c)(3) tax-exempt public non-profit organization with a mailing address of P.O. Box 297, South Egremont, MA 01258 (the “Sponsor”) (each a “Party” and together the “Parties”), and amends that certain SPONSORED RESEARCH AGREEMENT, effective as of October 12, 2007, by and between the Parties (the “Agreement”), as follows.

Sarepta Therapeutics, Inc. – SEVENTH AMENDMENT TO LEASE (May 3rd, 2018)

THIS SEVENTH AMENDMENT TO LEASE (this “Seventh Amendment”) is made as of April 27, 2018, by and between ARE-MA REGION NO. 38, LLC, a Delaware limited liability company (“Landlord”), and SAREPTA THERAPEUTICS, INC., a Delaware corporation (“Tenant”).

Sarepta Therapeutics, Inc. – Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments — First quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $64.6 million — (May 3rd, 2018)

— Sarepta signs exclusive partnership and buy-out option with Myonexus Therapeutics; pipeline expands from 16 to 21 programs —

Sarepta Therapeutics, Inc. – Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results and Recent Corporate Developments — Fourth quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $57.3 million — — Cash and investment balance of $1.1 billion as of December 31, 2017 — (March 1st, 2018)

CAMBRIDGE, Mass., March 1, 2018 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today reported financial results for the three and twelve months ended December 31, 2017.

Sarepta Therapeutics, Inc. – [Executive Name] c/o Sarepta Therapeutics, Inc. (March 1st, 2018)
Sarepta Therapeutics, Inc. – To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 A/C: 052201829 From: Goldman Sachs & Co. LLC Re: Base Call Option Transaction Date: November 8, 2017 (November 14th, 2017)

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Goldman Sachs & Co. LLC (“Dealer”) and Sarepta Therapeutics, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.

Sarepta Therapeutics, Inc. – Sarepta Therapeutics Prices $475 Million of Convertible Senior Notes Due 2024 — Chief executive officer purchases approximately $2 million of shares of Sarepta’s common stock — (November 14th, 2017)

CAMBRIDGE, Mass., November 8, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the pricing of $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024. The notes are being offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Sarepta has also granted the initial purchasers of the notes an option to purchase up to an additional $95 million aggregate principal amount of the notes, solely to cover over-allotments. The sale of the notes to the initial purchasers is expected to settle on November 14, 2017, subject to customary closing conditions.

Sarepta Therapeutics, Inc. – JPMorgan Chase Bank, National Association London Branch (November 14th, 2017)
Sarepta Therapeutics, Inc. – Sarepta Therapeutics Announces Exercise of Initial Purchasers’ Option to Purchase Additional Convertible Senior Notes Due 2024 —Capped call transactions raise the effective conversion price of the notes to $104.88, subject to future adjustments— (November 14th, 2017)

CAMBRIDGE, Mass., November 9, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced the exercise in full on the initial purchasers’ option to purchase an additional $95 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024. The notes are being offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The sale of the notes to the initial purchasers is expected to settle on November 14, 2017, subject to customary closing conditions.

Sarepta Therapeutics, Inc. – JPMorgan Chase Bank, National Association London Branch (November 14th, 2017)
Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC. 1.500% Convertible Senior Notes due 2024 Purchase Agreement (November 14th, 2017)
Sarepta Therapeutics, Inc. – Sarepta Therapeutics Announces Proposed Offering of $375 Million of Convertible Senior Notes Due 2024 — Chief executive officer indicates interest in purchasing $2 million of shares of Sarepta’s common stock — (November 14th, 2017)

CAMBRIDGE, Mass., November 7, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that it intends to offer, subject to market and other conditions, $375 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024. The notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Sarepta also expects to grant the initial purchasers of the notes an option to purchase up to an additional $75 million aggregate principal amount of the notes, solely to cover over-allotments.

Sarepta Therapeutics, Inc. – SAREPTA THERAPEUTICS, INC., as Issuer AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of November 14, 2017 1.50% Convertible Senior Notes due 2024 (November 14th, 2017)

INDENTURE dated as of November 14, 2017 between SAREPTA THERAPEUTICS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK NATIONAL ASSOCIATION, a national banking association, as trustee (the “Trustee,” as more fully set forth in Section 1.01).

Sarepta Therapeutics, Inc. – To: Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Attention: General Counsel Telephone No.: (617) 274-4000 A/C: 052201829 From: Goldman Sachs & Co. LLC Re: Additional Call Option Transaction Date: November 9, 2017 (November 14th, 2017)

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Goldman Sachs & Co. LLC (“Dealer”) and Sarepta Therapeutics, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. Each party further agrees that this Confirmation together with the Agreement evidence a complete binding agreement between Counterparty and Dealer as to the subject matter and terms of the Transaction to which this Confirmation relates, and shall supersede all prior or contemporaneous written or oral communications with respect thereto.

Sarepta Therapeutics, Inc. – FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (November 14th, 2017)

THIS FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (this “Amendment”) is dated as of November 7, 2017, by and among SAREPTA THERAPEUTICS, INC., a Delaware corporation (“Borrower”), MIDCAP FINANCIAL TRUST, a Delaware statutory trust in its capacity as administrative agent (in such capacity, “Agent”) for the lenders under the Credit Agreement (as defined below) (“Lenders”), and the Lenders.

Sarepta Therapeutics, Inc. – FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT (November 14th, 2017)

THIS FIRST AMENDMENT TO CREDIT AND SECURITY AGREEMENT (this “Amendment”) is dated as of November 7, 2017, by and among SAREPTA THERAPEUTICS, INC., a Delaware corporation (“Borrower”), MIDCAP FUNDING IV TRUST, a Delaware statutory trust in its capacity as administrative agent (in such capacity, “Agent”) for the lenders under the Credit Agreement (as defined below) (“Lenders”), and the Lenders.

Sarepta Therapeutics, Inc. – CONSULTING AGREEMENT (November 1st, 2017)

THIS CONSULTING AGREEMENT (this “Agreement”), dated as of August 17, 2017 (the “Effective Date”), is entered into by and between by and between Sarepta Therapeutics, Inc., a Delaware corporation (the “Company”), and Edward M. Kaye, M.D. (the “Consultant”).

Sarepta Therapeutics, Inc. – Guriqbal S. Basi, Ph.D. Senior Vice President, Chief Scientific Officer…. c/o Sarepta Therapeutics, Inc. (November 1st, 2017)
Sarepta Therapeutics, Inc. – Catherine Stehman-Breen c/o Sarepta Therapeutics, Inc. (November 1st, 2017)